NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study is a prospective single arm trial designed to study the safety, feasibility and
preliminary efficacy of a medical device, NovoTTF-200A used concomitantly with standard
adjuvant treatment for newly diagnosed glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Hackensack Meridian Health Hackensack University Medical Center